Egetis Therapeutics & Anovo Unite for MCT8 Patients
January 2, 2024
Egetis Therapeutics is an innovative pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
What is MCT8 Deficiency (Allan-Herndon-Dudley Syndrome)?
MCT8 deficiency, a rare and debilitating disorder also known as Allan-Herndon-Dudley Syndrome, poses significant challenges for affected individuals and their loved ones. This genetic condition primarily affects brain development and function, leading to developmental delays, muscle weakness, and neurological impairments. Despite its rarity, the impact of Allan-Herndon-Dudley Syndrome is profound, underscoring the urgent need for effective treatments and interventions to improve the quality of life for those affected.
Egetis Therapeutics Partners with Anovo
At Anovo, we’re proud to work with Egetis Therapeutics to help more patients access their innovative new therapy for MCT8 deficiency. Since there is currently no available approved treatment for MCT8 deficiency, our partnership enables us to administer the Egetis Early Access Program (EAP), providing hope and support to patients and families facing the challenges of MCT8 deficiency. Together, we’re committed to advancing the field of rare disease treatment, working towards a brighter future for our patients and their caregivers.
Related Posts
Why Exclusivity Matters: Redefining Patient-Centricity in Rare and Ultra-Rare Drug Commercialization
In the rare disease space, every patient story is deeply personal, and every barrier to access feels monumental. From navigating…
June 4, 2025
The Heart of Our Success: How Our HR Team Fuels Growth & Culture
At Anovo, we know that our success starts with our people. Behind every dedicated team member, every seamless patient experience,…
May 19, 2025
Investing in Training to Elevate Patient Care
At Anovo, we believe that exceptional patient support starts with a well-trained, knowledgeable team. As we continue to grow, we’ve…
April 1, 2025